Sabine D. Brookman-May, Professor of Urology at München University, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X about a paper by Tyler S. Garman and Max R. Kates published in European Urology:
“Great Letter to the Editor Max Kates, reflecting the most important aspects and remaining questions related to recent trials in HR NMIBC POTOMAC Crest Alban
- Beyond efficacy and toxicity, these trials offer new insights into early stage bladder cancer biology
- Risk-Benefit assessment is important balancing high risk of side effects with moderate risk of recurrence/progression before generally recommending combinations
- BCG performs better than we thought: 1-yr recurrence ~15% with BCG induction + maintenance – far lower than the commonly cited ~40%, likely reflecting improved adherence to maintenance therapy.
- Early vs late recurrence matters + are early recurrences true failures or incomplete initial TURBT rather than treatment resistance
What’s next? Consistent integration of correlative studies using urine, tissue, and AI-based biomarkers could improve risk stratification and identify patients most likely to benefit from emerging therapies.”
Title: Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221–34
Authors: Tyler S. Garman, Max R. Kates
You can read the Full Article in European Urology.
More posts featuring Sabine D. Brookman-May.